The State of Cannabis Banking for 2026: Rescheduling, Descheduling, and the Future of Financial Compliance

The Big Picture: Why 2026 Matters

Cannabis banking sits at a crossroads. The industry has grown dramatically, with more financial institutions entering the space than ever before. Yet the regulatory framework remains fragmented, uncertain, and—in many respects—inadequate for the scale of activity now taking place.

2026 promises to be a pivotal year. Federal rescheduling discussions continue, FinCEN guidance remains stalled, and the emergence of cannabis-derived products has introduced new compliance complexities that few financial institutions anticipated. Understanding these dynamics is essential for any FI currently serving—or considering serving—cannabis-related businesses.

Rescheduling: Why the Impact Is Being Overestimated

Much of the industry discourse around rescheduling assumes it would be a transformative event for cannabis banking. The reality is more nuanced. Rescheduling cannabis from Schedule I to Schedule III would primarily affect tax treatment under Section 280E, but it would not fundamentally change the banking compliance landscape.

Cannabis would remain a controlled substance. FinCEN's guidance on filing Suspicious Activity Reports (SARs) for marijuana-related businesses would likely remain in effect. The Cole Memo-era framework that underpins most cannabis banking compliance programs would continue to apply. Financial institutions should prepare for rescheduling, but they should not expect it to simplify their compliance obligations significantly.

FinCEN: The Guidance That Isn't Moving

FinCEN's 2014 guidance on marijuana banking remains the foundation of cannabis banking compliance, despite being over a decade old and predating the explosion of state-legal cannabis markets. The guidance was designed for a much smaller, less complex industry.

Financial institutions have been waiting for updated FinCEN guidance that reflects the current reality of cannabis banking. That update has not materialized, and there is little indication it will in the near term. FIs must continue to build their compliance programs around existing guidance while preparing for potential changes.

The Cannabis Shock: From "Lower Risk" to Regulatory Wildcard

Perhaps the most underappreciated development in cannabis banking is the emergence of cannabis-derived THC products. The 2018 Farm Bill legalized cannabis-derived products containing less than 0.3% delta-9 THC by dry weight. This created a legal pathway for products that are functionally similar to traditional cannabis but fall outside the scope of most cannabis banking compliance programs.

Financial institutions that viewed cannabis banking as lower risk are now confronting a more complex reality. Cannabis-derived products are subject to varying state regulations, and the line between legal cannabis products and illegal cannabis products is often blurry. FIs need to reassess their cannabis banking risk profiles and ensure their compliance programs account for these evolving risks.

Looking Ahead

The state of cannabis banking in 2026 demands a sophisticated, forward-looking approach. Financial institutions must balance the opportunities of a growing market against the realities of an evolving—and often uncertain—regulatory environment.

At Cogent Law, our cannabis banking attorneys work with financial institutions to build and maintain compliant, sustainable cannabis banking programs. For related analysis, explore our article on cannabis rescheduling and commercial lending implications, or watch our webinar on the executive order to reschedule cannabis. Discuss your cannabis banking strategy for 2026.